Nobivac® Lyme

Dogs

Diseases

Borrelia Burgdorferi Bacterin


The only Lyme vaccine which is licensed to aid in the prevention of subclinical arthritis and other signs of Lyme disease. The vaccine contains a traditional isolate targeted at OspA and a unique isolate proven to induce high levels of Borreliacideal antibodies to OspC1.1,2

Features and benefits 

  • The only Lyme vaccine designed to target the 2 key outer surface proteins (Osps) involved in disease transmission for a full level of protection.
  • Proven to induce borreliacidal antibodies that bind to OspA and OspC, forming a complex that attacks the cell membrane and kills Borrelia burgdorferi1,2
  • Proven to help prevent clinical disease such as arthritis2
  • Highly effective: no serologic evidence of exposure to B. burgdorferi2

Indication

  • For the vaccination of healthy dogs as an aid in the prevention of clinical disease and subclinical arthritis associated with Borrelia burgdorferi
  • Recommended for use in healthy dogs 8 weeks of age or older

Safety information

Proven safe and well tolerated in a field safety trial of more than 600 dogs1

  • Less than 1% of dogs experienced vaccine-related adverse reactions
  • 99.3% reaction-free
  • No dogs removed from the study
  • Since 2009, Nobivac Lyme has been safely administered to over 2 million dogs

Administration and Dosage

  • Subcutaneous injection
  • Two 1-mL doses given 2 to 4 weeks apart
  • Last dose may be given at 12 weeks of age
  • Annual revaccination with 1 dose is recommended
  • Available in a 25 x 1-mL dose

For further information, including complete directions and warnings, please see the product label.

Product label(s) and MSDS

References:

  1. Data on file, Merck Animal Health.
  2. LaFleur RL, Dant JC, Wasmoen TL, et al. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. Clin Vaccine Immunol. 2009;16(2):253–259.